Work

105P A single-arm, phase II, multicenter study of iparomlimab (QL1604) in patients (pts) with unresectable/metastatic deficient mismatch repair (dMMR)/microsatellite instability high (MSI-H) solid tumors

Year: 2023

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2023.10.240

Authors: W. Guo, F. Bi, J. Dong, C. Jin, Z. Niu, Y. Wang, M. Sun, T. Wang, D. Yu, Y. He, R. Zhang, X. Yin, W. Feng, M. Zhang, L. Li, B. Zhang, X. Kang

Institutions: Fudan University Shanghai Cancer Center, Sichuan University, West China Medical Center of Sichuan University, West China Hospital of Sichuan University, Kunming Medical University, Guangzhou Medical University Cancer Hospital, Guangzhou Medical University, Shandong University, Shandong Tumor Hospital, Shanxi Provincial Cancer Hospital, Shandong First Medical University, Wuxi Fourth People's Hospital, First Affiliated Hospital of Bengbu Medical College, Hebei Medical University, Fourth Hospital of Hebei Medical University, Hunan Cancer Hospital, Qilu Pharmaceutical Co., Ltd. (China)

Language: English

Topic: Cancer Immunotherapy and Biomarkers

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4389279783

FWCI:

Cites:

Cited by:

Related to: 10